A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC

Summary

This is an open-label phase II/III clinical trial enrolling patients with advanced HCC who have failed prior ICIs. The phase II portion consists of a part A dose-escalation stage and a part B dose-expansion stage. The phase III study will be initiated following discussions with National Medical Products Administration (NMPA) regarding the phase III protocol, based on accumulated data from phase II including safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD).

Timeline

Start

2026-05-13

Primary completion

2028-12-31

Completion

2029-06-30

Drugs

Indications